Fiste Oraianthi, Mavrothalassitis Evangelos, Kokkalis Alexandros, Anagnostakis Maximilian, Gomatou Georgia, Kontogiannis Athanasios, Karaviti Dimitra, Karaviti Eleftheria, Syrigos Nikolaos Konstantinos, Kotsakis Athanasios, Kotteas Elias Alexandros
Oncology Unit, Third Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, Sotiria General Hospital, 11527, Athens, Greece.
Department of Medical Oncology, University Hospital of Larissa, 41334, Larissa, Greece.
Clin Transl Oncol. 2025 Jun;27(6):2453-2460. doi: 10.1007/s12094-024-03814-9. Epub 2024 Dec 12.
Neoadjuvant systemic therapy (NAT) represents an attractive option for improved outcomes of early-stage breast cancer (BC) patients, as it can significantly reduce tumor burden thus permitting breast-conserving resections. Equally important, the eradication of viable cancer cells post-NAT, also known as pathological complete response (pCR), has emerged as a strong prognostic biomarker, reflecting tumor's biology and subsequent treatment responses. Yet to date, no validated markers predictive of pCR have been identified.
The present retrospective study aimed to explore the value of neutrophil-tolymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as potential predictors of pCR.
Despite no statistically significant associations have been reported, NLR and PLR dynamics during NAT, as longitudinal inflammatory phenotypes, merit further investigation in larger cohorts.
In the future, the integration of a comprehensive inflammatory biomarker panel into clinical practice could assist in a priori treatment selection process.
新辅助全身治疗（NAT）是改善早期乳腺癌（BC）患者预后的一个有吸引力的选择，因为它可以显著减轻肿瘤负担，从而允许进行保乳手术。同样重要的是，NAT后存活癌细胞的根除，即病理完全缓解（pCR），已成为一种强大的预后生物标志物，反映了肿瘤的生物学特性和后续治疗反应。然而，迄今为止，尚未发现可预测pCR的经过验证的标志物。
本回顾性研究旨在探讨中性粒细胞与淋巴细胞比值（NLR）和血小板与淋巴细胞比值（PLR）作为pCR潜在预测指标的价值。
尽管未报告有统计学意义的关联，但NAT期间作为纵向炎症表型的NLR和PLR动态变化，值得在更大的队列中进一步研究。
未来，将综合炎症生物标志物面板整合到临床实践中可能有助于进行先验治疗选择。
